ADB-FUBINACA

• CAT Number: R064748
• CAS Number: 1445583-51-6
• Molecular Formula: C21H23FN4O2
• Molecular Weight: 382.44
• Purity: ≥95%
• Synonyms: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
• Storage: -20°C
• IUPAC Name: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide
• InChI: InChI=1S/C21H23FN4O2/c1-21(2,3)18(19(23)27)24-20(28)17-15-6-4-5-7-16(15)26(25-17)12-13-8-10-14(22)11-9-13/h4-11,18H,12H2,1-3H3,(H2,23,27)(H,24,28)
• InChIKey: ZSSGCSINPVBLQD-UHFFFAOYSA-N
• SMILES: CC(C)(C)C(C(=O)N)NC(=O)C1=NN(C2=CC=CC=C21)CC3=CC=C(C=C3)F

ADB-FUBINACA(CAT: R064748) is a synthetic cannabinoid that acts as a potent agonist for the CB1 and CB2 cannabinoid receptors, mimicking the effects of delta-9-tetrahydrocannabinol (THC), the active component in cannabis. Originally developed for pharmaceutical research, it was never approved for medical use but emerged as a popular recreational drug in synthetic cannabinoid products. ADB-FUBINACA has been linked to severe adverse effects, including toxicity, extreme sedation, psychosis, and, in some cases, fatalities. Its strong binding affinity to cannabinoid receptors makes it significantly more potent than THC, posing substantial risks in recreational use. The compound is frequently encountered in forensic and toxicological studies due to its role in synthetic drug abuse.